Table V.
Analysis of miRNA expression levels in GCB, non-GCB DLBCL subtypes and control groups (mean±SD).
| Groups | miR-19a-3p | miR-19b-3p | miR-193a-3p | miR-370-3p | miR-1275 | miR-490-5p | miR-630 | miR-665 |
|---|---|---|---|---|---|---|---|---|
| Control (LRH) (n=15) | 1.134±0.576 | 1.132±0.503 | 1.269±0.904 | 1.172±0.728 | 1.186±0.788 | 1.164±0.655 | 1.095±0.524 | 1.085±0.430 |
| GCB (n=5) | 0.682±0.308 | 0.573±0.397a | 0.582±0.263a | 0.230±0.111a | 0.975±0.568 | 0.437±0.406a | 1.860±1.628a | 0.949±0.372 |
| Non-GCB (n=10) | 0.982±0.760 | 0.580±0.396a | 0.531±0.259a | 0.239±0.228a | 1.461±0.807 | 0.466±0.303a | 2.287±1.061a | 1.685±1.067 |
a
P<0.05 vs. control. DLBCL, diffuse large B-cell lymphoma; LRH, lymph node reactive hyperplasia; GCB, germinal center B-cell like; miR/miRNA, microRNA.